Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The d...
Main Authors: | Kelsey E. Lewis, Karen H. Lu, Amber M. Klimczak, Samuel C. Mok |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/10/2/57 |
Similar Items
-
BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
by: Tarinee Manchana, et al.
Published: (2020-08-01) -
BRCA1 and BRCA2 and Inherited Predisposition to Breast and Ovarian Cancers
by: Patricia N. Tonin
Published: (2002-12-01) -
Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome
by: Ashour M, et al.
Published: (2019-07-01) -
Clinical Presentation of Pelvic Tuberculosis Imitating Ovarian Malignancy
by: Yun-Ju Huang, et al.
Published: (2004-03-01) -
Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review
by: Lisa Krassuski, et al.
Published: (2019-08-01)